Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding Kidney International

Slides:

Advertisements

Similar presentations

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Advertisements

Volume 64, Issue 3, Pages (September 2003)

Nina Vasavada, Rajiv Agarwal Kidney International

Myoung J. Kang, Alistair Ingram, Hao Ly, Kerri Thai, James W. Scholey

Antioxidant Treatment Prevents Renal Damage and Dysfunction and Reduces Arterial Pressure in Salt-Sensitive Hypertension by Niu Tian, Kristina D. Thrasher,

Volume 19, Issue 8, Pages (May 2017)

Selenium-deficient diet induces renal oxidative stress and injury via TGF-β1 in normal and diabetic rats Alluru S. Reddi, Jaya S. Bollineni Kidney International

Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells Zhenmin Ni, Stephen Hou, Cyril H. Barton,

Volume 66, Issue 6, Pages (December 2004)

Plasma sodium and hypertension

Cyril H. Barton, Zehnmin Ni, Nosratola D. Vaziri Kidney International

Volume 59, Issue 5, Pages (May 2001)

Vitamin D deficiency and heart disease

Volume 66, Issue 6, Pages (December 2004)

Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats Julie Chao, Jenny J. Zhang, Kuei-Fu Lin,

Volume 64, Issue 3, Pages (September 2003)

Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats Eduardo Slatopolsky, Mario Cozzolino,

Vitamin E attenuates crystal formation in rat kidneys: Roles of renal tubular cell death and crystallization inhibitors H.-S. Huang, J. Chen, C.-F. Chen,

Volume 68, Issue 3, Pages (September 2005)

Volume 19, Issue 8, Pages (May 2017)

Hung-Chun Chen, Jinn-Yuh Guh, Juei-Hsiung Tsai, Yung-Hsiung Lai

Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension Tyrus Stewart, Flavia F. Jung, Jennifer Manning,

Endothelial-derived vasoactive mediators in polycystic kidney disease

Volume 69, Issue 2, Pages (January 2006)

Volume 76, Issue 3, Pages (August 2009)

Volume 67, Issue 1, Pages (January 2005)

Volume 61, Issue 1, Pages (January 2002)

Volume 65, Issue 5, Pages (May 2004)

Hemostasis in acute liver and kidney failure: nothing is as it seems

Enlightenment on liver lanthanum exposure

Hypertension promotes integrin expression and reactive oxygen species generation by circulating leukocytes Choong H. Kim, Nosratola D. Vaziri Kidney.

Volume 75, Issue 2, Pages (January 2009)

Volume 80, Issue 8, Pages (October 2011)

Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: Reversal by lifelong antioxidant supplementation Chang-de Zhan, Ram K. Sindhu, Nosratola.

Volume 57, Issue 5, Pages (May 2000)

Volume 68, Issue 6, Pages (December 2005)

P. Harding, L. Balasubramanian, J. Swegan, A. Stevens, W.F. Glass

Volume 69, Issue 10, Pages (May 2006)

Volume 67, Issue 1, Pages (January 2005)

Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells Z. Su, J. Zimpelmann, K.D. Burns Kidney.

Volume 61, Issue 5, Pages (May 2002)

Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression Klaus Höcherl, Frieder Kees, Bernhard K. Krämer,

Oral contraceptive administration aggravates nitric oxide synthesis inhibition-induced high blood pressure in female rats L.A. Olatunji, A.O. Soladoye

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 62, Issue 3, Pages (September 2002)

Proteinuria and hypertensive nephrosclerosis in African Americans

Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension Zhenmin Ni, Shahrooz Bemanian, Salah D. Kivlighn,

Volume 70, Issue 1, Pages (July 2006)

Kaihui Liang, Nosratola D. Vaziri Kidney International

Chien-Te Lee, Viet M. Huynh, Li-Wen Lai, Yeong-Hau H. Lien

Hydrogen: another gas with therapeutic potential

Volume 63, Issue 1, Pages (January 2003)

Circadian regulation of renal function

Volume 57, Issue 2, Pages (October 2000)

Nosratola D. Vaziri, Fariba Oveisi, Yaoxian Ding Kidney International

Nina Vasavada, Rajiv Agarwal Kidney International

Changbin Qiu, Chris Baylis Kidney International

Volume 63, Issue 2, Pages (February 2003)

Nosratola D. Vaziri, M.D., Kaihui Liang Kidney International

Cyril H. Barton, Zhemin Ni, Nosratola D. Vaziri Kidney International

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis Nosratola D. Vaziri, Tadashi Sato, Kaihui Liang

Salt sensitivity in genetically hypertensive rats of the Lyon strain

Is it the low-protein diet or simply the salt restriction?

Volume 68, Issue 1, Pages (July 2005)

Volume 62, Issue 5, (November 2002)

Quantitative estimation of renal blood flow by power Doppler ultrasonography in renovascular hypertensive dogs Tetsumasa Miyajima, Hiroshi Yokoyama,

Volume 61, Issue 4, Pages (April 2002)

Ronen Levi, Justin Silver Kidney International

Volume 66, Issue 1, Pages (July 2004)

Presentation transcript:

Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding Kidney International Volume 56, Issue 4, Pages 1492-1498 (October 1999) DOI: 10.1046/j.1523-1755.1999.00670.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Longitudinal measurements of arterial blood pressure in the normal control (•) group and rats treated with lead alone (▪) or lead plus vitamin E supplement (▴) during a 12-week treatment period.N = 6 in each group; *P < 0.01 vs. control group; +P < 0.05 vs. Pb group. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Upper panel depicts representative Western blot of nitrotyrosine in the plasma of two normal control rats (NL), two rats treated with lead alone (Pb), and two rats treated with lead plus vitamin E (Pb + E) for a 12-week period. The corresponding group data are illustrated in the lower panel. N = 6 in each group; *P < 0.01 vs. other groups, analysis of variance. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Longitudinal measurements of plasma nitrotyrosine abundance in the normal control (•) group and rats treated with lead alone (▪) or lead plus vitamin E supplement (▴) during a 12-week treatment period.N = 6 at each time point in each group; *P < 0.01 vs. the other groups, analysis of variance. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Upper panel depicts representative Western blot of nitrotyrosine in the brain of two normal control rats (NL) and two rats each treated with lead alone (Pb) or lead plus vitamin E (Pb + E) for a 12-week period. The corresponding group data are illustrated in the lower panel. N = 6 in each group; *P < 0.02 vs. other groups, analysis of variance. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Upper panel depicts representative Western blot of nitrotyrosine in the liver of two normal control rats (NL) and two rats each treated with lead alone (Pb) or lead plus vitamin E (Pb + E) for a 12-week period. The corresponding group data are illustrated in the lower panel. N = 6 in each group; *P < 0.01 vs. other groups, analysis of variance. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 6 Upper panel depicts representative Western blot of nitrotyrosine in the kidney of two normal control rats (NL) and two rats each treated with lead alone (Pb) or lead plus vitamin E (Pb + E) for a 12-week period. The corresponding group data are illustrated in the lower panel. N = 6 in each group; *P < 0.03 vs. other groups, analysis of variance. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 7 Upper panel depicts representative Western blot of nitrotyrosine in the heart of two normal control rats (NL) and two rats each treated with lead alone (Pb) or lead plus vitamin E (Pb + E) for a 12-week period. The corresponding group data are illustrated in the lower panel. N = 6 in each group; *P < 0.01 vs. other groups, analysis of variance. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 8 Representative Western blots of nitrotyrosine in brain, heart, kidney, liver and plasma of two untreated normal control (NL) rats and two vitamin E-treated normal control (NL + E) rats. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 9 Group data illustrating (A) brain, (B) heart, (C) kidney, (D) liver, and (E) plasma nitrotyrosine abundance in six untreated normal control (NL) rats and six vitamin E-treated control (NL + E) rats. No significant difference was found in tissue nitrotyrosine abundance in any of the tested tissues between the two groups. Kidney International 1999 56, 1492-1498DOI: (10.1046/j.1523-1755.1999.00670.x) Copyright © 1999 International Society of Nephrology Terms and Conditions